Roscoff-based SeaBeLife, a BioTech firm creating progressive drug candidates supposed to dam mobile necrosis, as we speak broadcasts a pre-Sequence A funding spherical value €2 million.
The financing was led by historic investor iXLife, alongside different longstanding shareholders Breizh Angels, WeLikeStartup, Angels Santé and the Enterprise Angels des Grandes Ecoles. This spherical welcomes new traders, together with INEXT and Femmes Enterprise Angels, the primary women-only enterprise angels’ community in Europe.
“The renewed backing from our longstanding traders, along with the addition of recent companions, is a transparent sign of confidence in our imaginative and prescient and growth technique, and I’m extraordinarily grateful for his or her help,” stated Morgane Rousselot, PhD, CEO and Co-founder of SeaBeLife. “This fundraising is a decisive step in direction of scientific trials and reinforces our ambition to create a brand new era of cutting-edge remedies able to blocking two main pathways for programmed cell loss of life. We at the moment are actively making ready for a Sequence A funding spherical to maintain this momentum.”
Based in 2019, SeaBeLife focuses on creating novel small molecules that concurrently goal two main regulated cell loss of life pathways, necroptosis and ferroptosis, to satisfy key medical wants in acute, uncommon or power indications the place there isn’t any therapeutic various.
This primary-in-class strategy is reportedly distinctive, as there may be at the moment no twin inhibitor concentrating on these pathways obtainable available on the market. At the beginning of 2025, the corporate delivered promising preclinical efficacy outcomes for its SBL03 drug candidate in geographic atrophy, a extreme type of dry AMD.
The corporate is focusing its efforts on two flagship programmes: SBL03 for dry AMD, and SBL01 for extreme acute hepatitis, two excessive medical want indications for which the potential market is value a number of billion euros.
“We have now backed SeaBeLife for a number of years and the newest in vivo knowledge validates the worth and potential of the corporate’s dual-targeted strategy. By concurrently blocking two types of regulated cell loss of life, SeaBeLife uniquely shields organs from injury, highlighting its transformative potential to offer sufferers with uncommon or power illnesses with a brand new therapeutic choice,” stated Jean-Pierre Kinet, chairman of iXLife.
This funding marks a key milestone for SeaBeLife by supporting the event of two of the corporate’s drug candidates – one geared toward dry age-related macular degeneration (AMD) and the opposite for extreme acute hepatitis. The primary scientific trial is about to begin in 2026.
Additional to this financing spherical, Marie-Pierre Sbardella, normal secretary of Femmes Enterprise Angels, joins the SeaBeLife Strategic Committee.
“We at INEXT are impressed by SeaBeLife’s disruptive know-how, which concurrently blocks two regulated cell loss of life pathways, defending the organs from critical illnesses. Its first-in-class strategy, which is supported by promising preclinical outcomes, positions SeaBeLife as a key participant in the way forward for biotech. We’re proud to have contributed to this fundraising and to help the corporate’s development,” stated Eric Valat, chairman of INEXT.
Since inception, SeaBeLife has raised €9 million in capital and public financing. It’s led by CEO and Co-founder Morgane Rousselot, who holds a PhD in biochemistry from Sorbonne College/French Nationwide Middle for Scientific Analysis (CNRS)/Roscoff Marine Station.
The corporate relies on the analysis work of Stéphane Bach, PhD (CNRS), Marie-Thérèse Dimanche-Boitrel (Analysis Institute for Environmental and Occupational Well being — IRSET) and Claire Delehouzé, PhD, scientific director and accomplice.
